Phase II study of Radium ‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

ConclusionsRa ‐223 with hormonal therapy showed possible efficacy in HR+ bone‐dominant breast cancer metastasis, and adverse events were tolerable. We plan to further investigate the clinical application of Ra‐223 in these patients. (NCT02366130).

Source: Cancer Medicine - December 17, 2019 Category: Cancer & Oncology Authors: Naoto T. Ueno, Rie K. Tahara, Takeo Fujii, James M. Reuben, Hui Gao, Babita Saigal, Anthony Lucci, Toshiaki Iwase, Nuhad K. Ibrahim, Senthil Damodaran, Yu Shen, Diane D. Liu, Gabriel N. Hortobagyi, Debu Tripathy, Bora Lim, Beth A. Chasen Tags: ORIGINAL RESEARCH Source Type: research